Evaluation of opioid modulation in major depressive disorder

Area of Science:

• Psychiatry
• Neuroscience
• Pharmacology

Background:

• Opioids show antidepressant effects but carry addiction risks.
• Major depressive disorder (MDD) requires novel therapeutic strategies.
• Buprenorphine (BUP) is a partial μ-opioid agonist; samidorphan (SAM) is a potent μ-opioid antagonist.

Purpose of the Study:

• To assess if BUP/SAM combination therapy offers antidepressant activity without addictive potential.
• To evaluate the safety and efficacy of BUP/SAM in treating MDD.
• To explore balanced opioid receptor modulation as a novel psychiatric treatment.

Main Methods:

• A placebo-controlled crossover study assessed BUP/SAM pharmacodynamics in opioid-experienced adults.
• A subsequent 1-week placebo-controlled parallel-group study in MDD patients evaluated safety and efficacy.
• Dose-dependent opioid effects were measured using pupillometry and self-report questionnaires.

Main Results:

• Increasing SAM doses with fixed BUP reduced opioid effects, including euphoria and drug liking.
• The 1:1 BUP/SAM ratio, associated with maximal opioid blockade, showed significant improvement in HAM-D17 scores (p=0.032).
• The 1:1 BUP/SAM ratio demonstrated nearly significant improvement in MADRS scores (p=0.054) and was well tolerated.

Conclusions:

• Buprenorphine/samidorphan combination therapy demonstrated antidepressant activity in MDD patients.
• Balanced agonist-antagonist opioid modulation is a novel approach for MDD treatment.
• This strategy may hold potential for treating other psychiatric disorders.